Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease.
about
Parkinson's disease: gene therapiesPrimary skin fibroblasts as a model of Parkinson's diseaseEffect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation.Glial cell line-derived neurotrophic factor gene delivery via a polyethylene imine grafted chitosan carrier.Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination toolAdvances in gene therapy for movement disorders.Neurogenesis as a potential therapeutic strategy for neurodegenerative diseasesA regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.Use of Encapsulated Stem Cells to Overcome the Bottleneck of Cell Availability for Cell Therapy Approaches.Stem cell microencapsulation for phenotypic control, bioprocessing, and transplantationTrophic factor gene therapy for Parkinson's disease.Carriers in cell-based therapies for neurological disorders.Current Neurogenic and Neuroprotective Strategies to Prevent and Treat Neurodegenerative and Neuropsychiatric Disorders.Gene therapy for neurological disorders.Glial cell line-derived neurotrophic factor: characterization of mammalian posttranslational modifications.Controlled release of GDNF reduces nerve root-mediated behavioral hypersensitivity.An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS).Potential cellular and regenerative approaches for the treatment of Parkinson's disease.Simultaneous Transplantation of Fetal Ventral Mesencephalic Tissue and Encapsulated Genetically Modified Cells Releasing GDNF in a Hemi-Parkinsonian Rat Model of Parkinson's Disease.Combination of cell transplantation and glial cell line-derived neurotrophic factor-secreting encapsulated cells in Parkinson's disease
P2860
Q26824184-72906D1A-B869-4C1D-B6E2-378E2A0F55A9Q26999310-6C493ABA-20FE-4AD3-B418-E1C149931AE1Q33267617-E0C72E57-6D4B-45BB-8F48-4CB98CD6158FQ33857756-46C1F1D9-64AD-4E8C-BB2E-337F1D2EDF03Q33886377-F7AF0F7A-E3C0-43C5-B30D-A1DD907E7C5CQ34656049-C34893CD-6373-4F3B-B8E3-0F7DD49E36F8Q36569731-9E8150BC-4AD5-4DF9-B65C-A5ACC03540F6Q36744851-9C4B6BF8-212F-4535-BC78-17F31D551188Q37782267-49EE5CD5-E09E-408C-8B13-38ABCD146AB7Q38067344-37F12BA8-6A12-4E09-8253-81FABF732869Q38079792-5FD1633A-0718-4B42-9BF8-529A7A44372DQ38220613-E27CB5EC-9521-4B63-A3DA-6855B6075566Q38587566-B370C06F-E2FE-4696-B9C2-C83AB15D6E05Q38661071-2501D1DA-24F3-434C-B5FB-79B2CFBC6D2DQ39213096-79E9F1F8-A1ED-45CA-90E9-C3141B93FF56Q39960337-C5A9D89A-B6B1-4C6E-A12D-85C1B0B95645Q43176313-33683930-6998-41E4-88C8-E632E57EE96FQ43198086-C83E7F2D-A121-4666-905D-874BB32C3D03Q47234370-9AEBA90D-EA4E-4CD6-A4FE-448F5B6D85E1Q59137582-400DE9D9-45F7-428E-90CF-2F573455B132
P2860
Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Transient striatal delivery of ...... al model of Parkinson disease.
@en
type
label
Transient striatal delivery of ...... al model of Parkinson disease.
@en
prefLabel
Transient striatal delivery of ...... al model of Parkinson disease.
@en
P2093
P1476
Transient striatal delivery of ...... al model of Parkinson disease.
@en
P2093
Ali Sajadi
Christophe Lo Bianco
Jean-Charles Bensadoun
Patrick Aebischer
P304
P356
10.1016/J.NBD.2005.10.006
P577
2005-11-21T00:00:00Z